Lilly agrees to acquire Centessa Pharmaceuticals for about $6.3 billion upfront

Eli Lilly announced on March 31, 2026 that it had reached a definitive agreement to buy Centessa Pharmaceuticals, a clinical-stage company working on a new class of drugs for narcolepsy and other sleep-wake disorders, for about $6.3 billion in upfront cash plus contingent payments worth up to roughly $1.5 billion more ^[1]. Lilly completed the acquisition on June 24, 2026 ^[2].

The terms

Lilly agreed to pay $38.00 in cash per share for all of Centessa's shares and American Depositary Shares, plus one non-transferable contingent value right (CVR) worth up to $9.00 more per share, for total potential consideration of up to $47.00 per share ^[1]. The upfront cash represents an aggregate equity value of about $6.3 billion, and the CVR represents an additional potential aggregate equity value of about $1.5 billion ^[1].

The CVR pays out only if specific regulatory milestones are hit: $2.00 per CVR if the U.S. Food and Drug Administration approves cleminorexton (formerly ORX750) or ORX142 for narcolepsy type 2 before the fifth anniversary of closing; $5.00 per CVR for an FDA approval in idiopathic hypersomnia in the same window; and $2.00 per CVR upon the first FDA approval of either drug in any indication before January 1, 2030 ^[1]. Lilly's announcement cautioned that there is no assurance any CVR payments will be made ^[1].

The upfront cash price was a premium of about 40.5% to the 30-day volume-weighted average trading price of Centessa's ADSs through March 30, 2026 ^[1]. Investors affiliated with Medicxi Ventures, Index Ventures and General Atlantic, holding about 24.1% of Centessa's outstanding shares, signed agreements to vote for the deal ^[1]. The transaction was structured as a scheme of arrangement under the laws of England and Wales and required approval by Centessa shareholders and sanction by the High Court of Justice of England and Wales ^[1].

What Lilly is buying

Centessa is developing orexin receptor 2 (OX2R) agonists, drugs aimed at the brain system that governs the sleep-wake cycle ^[1]. Its lead candidate, cleminorexton, has been studied in Phase 2a trials in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, and the company describes the results as a potential best-in-class profile ^[1]. The portfolio also includes additional clinical and preclinical assets, including ORX142 ^[1].

"The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling," said Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, when the deal closed ^[2]. Centessa CEO Mario Alberto Accardi said the combination would "accelerate the advancement of our orexin portfolio across a broad range of neuroscience indications" ^[1].

No Phase 3 results, filing dates or pricing information for cleminorexton were disclosed in the announcements. Whether and when either drug reaches the market is not yet known.

Why it matters for patients

If you take semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), this deal does not change your medicine, its supply or its price. Neither cleminorexton nor ORX142 is a GLP-1 drug, and the announcements say nothing about Lilly's incretin products ^[1][2].

What it does show is where Lilly is directing the money. Industry coverage has framed Lilly's 2026 pipeline as being fueled by its incretin franchise — the tirzepatide and orforglipron (Foundayo) business — with proceeds flowing into other therapeutic areas ^[3]. Multibillion-dollar purchases like this one, and Lilly's separate acquisition of AtaiBeckley in treatment-resistant depression, are how that reinvestment shows up ^[2].

For people with narcolepsy or idiopathic hypersomnia, the practical consequence is that an experimental drug that had been in a small company's hands now sits inside one of the world's largest drugmakers, with more capital behind trials. That can speed development, but a deal closing is not evidence that a drug works or that regulators will approve it. The CVR structure itself makes that explicit: a large part of the price is payable only if FDA approvals actually arrive ^[1].

What happens next

The deal was announced March 31, 2026 and completed June 24, 2026 ^[1][2]. The CVR clock for a first FDA approval in any indication runs to January 1, 2030, and the narcolepsy type 2 and idiopathic hypersomnia milestones run to the fifth anniversary of closing ^[1]. Lilly said it would reflect the transaction in its financial results and guidance after closing ^[1].